FLT3 and acute myeloid leukemia: Similarly, sorafenib or other FLT3 inhibitors under clinical studies may synergistically enhance the therapeutic efficacies of chemotherapeutics by downregulating Chk1-mediated G2/M arrest specifically in refractory AML cases with FLT3-ITD.